Follow on Google News News By Tag * Limited Distribution * Imbruvica * Speciality Pharmacy * Oncology * Mantle Cell Lymphoma * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Diplomat receives limited distribution contract for IMBRUVICA™ (ibrutinib)By: Diplomat IMBRUVICA™, a Brutton’s Tyrosine Kinase (BTK) Inhibitor, is an oral drug available in 140 mg, 90 capsule bottles and 140 mg, 120 capsule bottles. Full prescribing information is available at www.IMBRUVICA.com. “We are pleased to partner with Pharmacyclics and Janssen Biotech, Inc. as a specialty pharmacy provider of IMBRUVICA™,” Diplomat’s high-tech, high-touch approach, which achieved 98% patient and prescriber satisfaction ratings in 2012, includes timely prescription delivery, side effect management support and 24 hour access to pharmacists and other specialists on the continuum of care. For IMBRUVICA™, Diplomat will also provide prior authorization management, co-pay support, and assistance to patients that meet certain financial criteria. IMBRUVICA™ is commercially available immediately. About Diplomat Diplomat serves patients and physicians in all 50 states as the nation’s largest independent specialty pharmacy. Headquartered in Flint, Mich., the company focuses on medication management programs for people with specialized or long-term medical needs, including cancer, HIV and multiple sclerosis. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues — always focused on increasing adherence and improving outcomes. Diplomat is accredited by URAC, PCAB, VAWD, ASHP and ACHC. Learn more at diplomatpharmacy.com (http://www.diplomatpharmacy.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|